Buchumschlag

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Olga M. Nardone, Nurulamin M. Noor, Aniruddh Prabhu, Alessandra Lim, Anirudh Krishnakumar, Abdulaziz Alajmi, Yuhong Yuan, Vipul Jairath, Maria Manuela Estevinho, Virginia Solitano
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
von: Nurulamin M. Noor, et al.
Veröffentlicht: (2024)

Systematic Review: Ultrasound Goes Echo—Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound
von: Sara Massironi, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
von: Purab Patel, et al.
Veröffentlicht: (2025)

Performance of bowel preparation quality scales in patients with Crohn's disease
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
von: Jakob B. Seidelin
Veröffentlicht: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
von: Jeffrey D. McCurdy, et al.
Veröffentlicht: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Editorial: Getting to the Heart of the Matter in IBD
von: Ashwin N. Ananthakrishnan
Veröffentlicht: (2025)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
von: Léa Sequier, et al.
Veröffentlicht: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
von: Ramin Ebrahimi, et al.
Veröffentlicht: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
von: Daniele Noviello, et al.
Veröffentlicht: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
von: Christian P. Selinger, et al.
Veröffentlicht: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
von: Guofu Mao, et al.
Veröffentlicht: (2026)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
von: Darcy Quinn Holt, et al.
Veröffentlicht: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
von: James L. Alexander, et al.
Veröffentlicht: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
von: Parul Tandon, et al.
Veröffentlicht: (2025)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
von: Xueneng Yang, et al.
Veröffentlicht: (2025)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
von: Adam S. Faye, et al.
Veröffentlicht: (2025)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
von: Keith Bodger
Veröffentlicht: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
von: Alice S. Day, et al.
Veröffentlicht: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
von: Giovanni Cammarota, et al.
Veröffentlicht: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
von: Maria Ling Lundström, et al.
Veröffentlicht: (2024)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
von: Shabari Shenoy, et al.
Veröffentlicht: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Meta‐analysis: Intestinal ultrasound to evaluate colonic contents and constipation
von: R. M. Mathias, et al.
Veröffentlicht: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
von: R. M. Mathias, et al.
Veröffentlicht: (2024)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
von: Fahim Ebrahimi, et al.
Veröffentlicht: (2024)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
von: Katherine L. Stone, et al.
Veröffentlicht: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
von: Xinli Chen, et al.
Veröffentlicht: (2024)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
von: Dhruv Ahuja, et al.
Veröffentlicht: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
von: Samantha Baillie, et al.
Veröffentlicht: (2025)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
von: Simone Chin, et al.
Veröffentlicht: (2025)

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
von: Parambir S. Dulai, et al.
Veröffentlicht: (2024)

Vedolizumab for Crohn's disease: Real‐world efficacy through a meta‐analytical lens
von: Maria Manuela Estevinho, et al.
Veröffentlicht: (2024)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
von: Natassia Tan, et al.
Veröffentlicht: (2025)